Last reviewed · How we verify
.75% bupivacaine
At a glance
| Generic name | .75% bupivacaine |
|---|---|
| Also known as | Blinded 3 blocks (2 bupivacaine, 1 sham block), Blinded 3 blocks (2 .75% bupivacaine, 1 sham block) |
| Sponsor | SI-BONE, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Hemorrhoid Surgery (NA)
- Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) (PHASE3)
- Pilot Herniorrhaphy Study for Postoperative Analgesia (PHASE2)
- Efficacy of EXPAREL vs. Bupivacaine (PHASE3)
- Observational Retrospective Study on Spinal Analgesia in Laparoscopic and Laparotomic Hysterectomy
- Bupivacaine With Epinephrine Over Diaphragm in Laparoscopy (PHASE4)
- Intrathecal MoRphine Versus Transabdominal Plane Block (TAP) Block for AnalGesic Management in Elective Caesarean Section (PHASE4)
- Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- .75% bupivacaine CI brief — competitive landscape report
- .75% bupivacaine updates RSS · CI watch RSS
- SI-BONE, Inc. portfolio CI